Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment (vol 14, pg 2249, 2024)


Por: Silverberg, JI, Wollenberg, A, Gold, LS, Del Rosso, J, Yosipovitch, G, Lio, P, Carrascosa, JM, Gallo, G, Ding, YX, Xu, ZH, Casillas, M, Pierce, E, Agell, H and Ständer, S

Publicada: 1 nov 2024 Ahead of Print: 1 oct 2024
Resumen:


Filiaciones:
Silverberg, JI:
 George Washington Univ, Sch Med, Washington, DC 20052 USA

Wollenberg, A:
 Univ Hosp Augsburg, Dept Dermatol & Allergy, Augsburg, Germany

 Ludwig Maximilians Univ Munchen, Dept Dermatol & Allergy, Munich, Germany

 UKSH Lubeck, Comprehens Ctr Inflammat Med, Lubeck, Germany

Gold, LS:
 Henry Ford Hlth Syst, Detroit, MI USA

Del Rosso, J:
 JDR Dermatol Res, Las Vegas, NV USA

Yosipovitch, G:
 Univ Miami, Miller Sch Med, Miami, FL USA

Lio, P:
 Northwestern Univ, Feinberg Sch Med, Chicago, IL USA

:
 Univ Autonoma Barcelona, Hosp Univ Germans Trias i Pujol, Serv Dermatol, Barcelona, Spain

Gallo, G:
 Eli Lilly & Co, Indianapolis, IN USA

Ding, YX:
 Eli Lilly & Co, Indianapolis, IN USA

Xu, ZH:
 CIMS Global LLC, Somerset, NJ USA

Casillas, M:
 Eli Lilly & Co, Indianapolis, IN USA

Pierce, E:
 Eli Lilly & Co, Indianapolis, IN USA

Agell, H:
 Almirall Prodesfarma, Barcelona, Spain

Ständer, S:
 Univ Hosp Munster, Ctr Chron Pruritus, Munster, Germany

 Univ Hosp Munster, Dept Dermatol, Munster, Germany
ISSN: 21938210





Dermatology and Therapy
Editorial
Springer Verlag, 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND, Reino Unido
Tipo de documento: Correction
Volumen: 14 Número: 11
Páginas: 3195-3196
WOS Id: 001339025300003
ID de PubMed: 39424713
imagen Green Submitted, gold

MÉTRICAS